(AVIR) Atea Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04683R1068
AVIR: Antiviral, COVID-19, Hepatitis, Inhibitors
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of antiviral therapies. Its lead product candidate, AT-527, is an oral antiviral currently in the Phase 3 SUNRISE-3 clinical trial for COVID-19 treatment. The company also develops bemnifosbuvir combined with ruzasvir, in Phase 2 trials for hepatitis C virus (HCV), and a protease inhibitor for COVID-19. Atea has a licensing agreement with MSD International GmbH for Ruzasvir, an NS5A inhibitor for HCV. Incorporated in 2012, Atea is headquartered in Boston, Massachusetts.
The companys pipeline reflects its focus on addressing significant viral infections, leveraging partnerships to enhance its development capabilities. Its strategic approach includes advancing multiple candidates through clinical stages, aiming to provide innovative solutions in the antiviral space.
Additional Sources for AVIR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AVIR Stock Overview
Market Cap in USD | 253m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2020-10-30 |
AVIR Stock Ratings
Growth 5y | -85.4% |
Fundamental | -66.9% |
Dividend | 0.0% |
Rel. Strength Industry | -20.7 |
Analysts | 3.33/5 |
Fair Price Momentum | 1.95 USD |
Fair Price DCF | - |
AVIR Dividends
No Dividends PaidAVIR Growth Ratios
Growth Correlation 3m | -50.8% |
Growth Correlation 12m | -80.4% |
Growth Correlation 5y | -89.3% |
CAGR 5y | -40.75% |
CAGR/Max DD 5y | -0.42 |
Sharpe Ratio 12m | -1.69 |
Alpha | -30.74 |
Beta | 1.01 |
Volatility | 60.22% |
Current Volume | 172.2k |
Average Volume 20d | 291.1k |
As of March 15, 2025, the stock is trading at USD 3.08 with a total of 172,230 shares traded.
Over the past week, the price has changed by +3.01%, over one month by -2.22%, over three months by -0.65% and over the past year by -20.00%.
No, based on ValueRay Fundamental Analyses, Atea Pharmaceuticals (NASDAQ:AVIR) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -66.85 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AVIR as of March 2025 is 1.95. This means that AVIR is currently overvalued and has a potential downside of -36.69%.
Atea Pharmaceuticals has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold AVIR.
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, AVIR Atea Pharmaceuticals will be worth about 2.2 in March 2026. The stock is currently trading at 3.08. This means that the stock has a potential downside of -29.22%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 7.4 | 140.3% |
Analysts Target Price | 7.4 | 140.3% |
ValueRay Target Price | 2.2 | -29.2% |